Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Hypertension Clear all
Completed No phase listed Observational

Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension

NCT02610660
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Association for Pediatric Pulmonary Hypertension
Other
Eligibility
3 Months to 18 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 1 Interventional

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

NCT00638742
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Artesia, California • Atlanta, Georgia • North Dartmouth, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 25, 2026, 7:59 AM EDT
Completed No phase listed Observational

Obesity in Pediatric Sickle Cell Disease: A New Phenomenon

NCT04676113
View directory record Official record
Conditions
Sickle Cell Disease, Obesity, Childhood, Hypertension, Hyperlipidemia in Children, Hyperglycemia
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
10 Years to 19 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 25, 2026, 7:59 AM EDT
Withdrawn Phase 2 Interventional

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

NCT00528827
View directory record Official record
Conditions
Hypertension
Interventions
Cardene® I.V.
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Beverly Hills, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 25, 2026, 7:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Ventricle Function Assessment Study

NCT06739057
View directory record Official record
Conditions
RV - Right Ventricular Abnormality, LV Dysfunction, Pulmonary Hypertension, TOF
Interventions
Not listed
Lead sponsor
HBI Solutions Inc.
Industry
Eligibility
Up to 18 Years
Enrollment
3,993 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

NCT01151410
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 25, 2026, 7:59 AM EDT
Recruiting No phase listed Observational

Office, Home, and Ambulatory Blood Pressure

NCT05297708
View directory record Official record
Conditions
Elevated Blood Pressure
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 19 Years
Enrollment
52 participants
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

NCT00147589
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
28
States / cities
Little Rock, Arkansas • Beverly Hills, California • Inglewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 25, 2026, 7:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vitamin D, Insulin Sensitivity, and Vascular Associations in Adolescents

NCT01041365
View directory record Official record
Conditions
Insulin Sensitivity, Flow-mediated Dilation, Arterial Stiffness
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 3 Interventional

Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age

NCT00244634
View directory record Official record
Conditions
Pediatric Hypertension
Interventions
candsartan cilexetil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 17 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
36
States / cities
Beverly Hills, California • Los Angeles, California • Madera, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2007 · Synced Oct 25, 2026, 7:59 AM EDT
Completed No phase listed Observational

Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients

NCT01023451
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 25, 2026, 7:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Social Needs Screening and Chronic Diseases Study (WE CARE)

NCT06903897
View directory record Official record
Conditions
Hyperlipidemias, Diabetes, Depression, Pediatric Asthma, Hypertension
Interventions
WE CARE SDOH System, Standard Pediatric Care
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Not listed
Enrollment
68,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 7:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Optimize Pediatric OCT Imaging

NCT06139523
View directory record Official record
Conditions
Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions
Investigational contact OCT system, Investigational noncontact OCT system:
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

NCT00001723
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
Interventions
Orlistat, Placebo
Drug
Lead sponsor
Jack Yanovski
NIH
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

NCT01150357
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 25, 2026, 7:59 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

NCT03492177
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
selexipag (Uptravi)
Drug
Lead sponsor
Actelion
Industry
Eligibility
2 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Iowa City, Iowa • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 7:59 AM EDT
Completed No phase listed Observational

Approaches and Decisions for Acute Pediatric TBI Trial

NCT04077411
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Observational
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 3 Interventional

The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

NCT00147615
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Los Angeles, California • Park Ridge, Illinois • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

NCT00716859
View directory record Official record
Conditions
Glaucoma
Interventions
Timolol, latanoprost
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
36 Weeks to 18 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Pembroke Pines, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 25, 2026, 7:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

NCT03310684
View directory record Official record
Conditions
Pediatric Disorder, Pediatric Obesity, Primary Hypertension
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
5 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 25, 2026, 7:59 AM EDT
Terminated No phase listed Observational

Pharmacokinetics and Pharmacdynamics of Sildenafil

NCT00718185
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Obtain blood specimens
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
28 Days and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Not applicable Interventional

Response of the Gut Microbiome and Circulating Metabolome to Diet in Children: Ancillary Study to KIDFIT (NCT03405246)

NCT03612479
View directory record Official record
Conditions
Gastrointestinal Microbiome, Metabolome, Pediatric Obesity, Dietary Approaches to Stop Hypertension
Interventions
KIDFIT Healthy, KIDFIT Safe
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
3 Years to 5 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 3 Interventional

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

NCT00255528
View directory record Official record
Conditions
Hypertension
Interventions
metoprolol succinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 16 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
30
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2007 · Synced Oct 25, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Results available

Olmesartan Pediatric Pharmacokinetic (PK) Study

NCT00151814
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
12 Months to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Little Rock, Arkansas • La Jolla, California • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Oct 25, 2026, 7:59 AM EDT